Publication | Closed Access

Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients

Rheumatoid DisorderRheumatologyAutoimmune DiseaseMetabolic Syndrome ComponentsMedicineRheumatic DiseasesPsoriatic ArthritisClinical DermatologyInflammatory Rheumatic DiseasePharmacotherapyPsoriatic Arthritis PatientsDermatologyPharmacology24-Month TreatmentRheumatoid Arthritis